1. CRISPR Therapy Approved for Sickle Cell: The UK has approved a groundbreaking CRISPR therapy for sickle cell disease and beta thalassemia. The therapy involves using CRISPR to turn on the gene for fetal hemoglobin in patients' blood stem cells. Clinical trials have shown promising results, with patients experiencing significant improvements. However, the therapy's high cost, expected to be at least $2 million, raises questions about affordability and coverage by healthcare systems.

    

2. US House Approves Gain-of-Function Ban: The US House of Representatives has passed an amendment to a 2024 spending bill that would ban NIH funding for gain-of-function research involving potential pandemic pathogens. The measure reflects concerns about the risks associated with making pathogens more dangerous for research purposes. The debate around gain-of-function research has intensified, with some linking it to the origins of the COVID-19 pandemic.

3. New Director for US National Cancer Institute (NCI): President Joe Biden has appointed Dr. Kimryn Rathmell, a physician-scientist from Vanderbilt University Medical Center, as the new director of the National Cancer Institute. Dr. Rathmell's expertise in tumor genomics and her contributions to understanding kidney cancer biology position her as a key figure in advancing cancer research. Her appointment aligns with Biden's Cancer Moonshot initiative to reduce cancer-related deaths.

4. Addressing Bias in Clinical Algorithms: A white paper from the Council of Medical Specialty Societies emphasizes the need to assess and reduce racial bias in medical algorithms systematically. While considering race in medical decisions can be beneficial, incorporating it into algorithms may perpetuate healthcare disparities. The paper calls for a formal review of each algorithm and increased education for clinicians and patients about their use.

5. NIH Funding Shift Towards Applied Research: Recent data from the National Institutes of Health (NIH) reveal a shift in extramural funding, with 56% allocated to applied research in 2022. Applied research, including translational and clinical studies, has received a larger share of funding compared to basic research. The change prompts discussions about the balance between applied and basic research and its implications for scientific advancements.

6. EU Extends Glyphosate Use with Restrictions: The European Commission has announced a 10-year extension of the approval for the herbicide glyphosate, subject to new conditions and restrictions. The decision includes a ban on using glyphosate to wither crops before harvest and measures to limit its spread to unintended plants. Glyphosate, known for its controversial use and potential environmental and health risks, remains a topic of scrutiny and regulatory measures.

These recent developments underscore the dynamic nature of scientific and health-related fields, reflecting advancements, regulatory decisions, and ongoing discussions on ethical and practical aspects.

You may be interested in:

EPA decision to tighten oversight of gene-edited crops draws mixed response

When the CRISPR gene editor landed in U.S. plant science labs a decade ago, allowing researchers to tweak a crop’s own DNA instead of pasting in foreign genes, hopes rose that it would pave the way for…